HC Wainwright Has Negative Outlook for ASND Q3 Earnings

Key Points

• HC Wainwright lowered Ascendis Pharma’s Q3 2026 EPS estimate to $1.09 from $1.16, while maintaining its Buy rating and $345 price target.
• Ascendis previously reported quarterly EPS of $1.03, missing the $1.71 consensus estimate by $0.68, although revenue of $387.22 million exceeded analysts’ $376.75 million forecast.
• Analyst sentiment remains positive overall, with the stock carrying a consensus Buy rating and an average price target of $304.95; shares opened at $263.04 after rising 6.1%.

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Research analysts at HC Wainwright dropped their Q3 2026 earnings estimates for shares of Ascendis Pharma A/S in a research report issued on Monday, August 31st. HC Wainwright analyst M. Kapoor now anticipates that the biotechnology company will post earnings of $1.09 per share for the quarter, down from their prior estimate of $1.16. HC Wainwright currently has a "Buy" rating and a $345.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is $3.90 per share. HC Wainwright also issued estimates for Ascendis Pharma A/S's Q4 2026 earnings at $1.58 EPS, Q1 2027 earnings at $1.65 EPS, Q2 2027 earnings at $2.34 EPS, Q3 2027 earnings at $3.04 EPS, Q4 2027 earnings at $4.23 EPS and FY2027 earnings at $11.25 EPS.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing analysts' consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.The business had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million.

Several other equities research analysts have also recently commented on ASND. Weiss Ratings raised Ascendis Pharma A/S from a "sell (d)" rating to a "hold (c)" rating in a research note on Wednesday, July 15th. Royal Bank Of Canada increased their price target on Ascendis Pharma A/S from $280.00 to $290.00 and gave the stock an "outperform" rating in a report on Friday, August 14th. Wall Street Zen raised shares of Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Evercore reaffirmed an "outperform" rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Finally, Barclays dropped their price objective on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an "overweight" rating on the stock in a report on Friday, August 14th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S currently has a consensus rating of "Buy" and an average price target of $304.95.

Ascendis Pharma A/S Stock Up 6.1%

Shares of NASDAQ:ASND opened at $263.04 on Tuesday. The company has a market capitalization of $16.41 billion, a price-to-earnings ratio of 20.41 and a beta of 0.39. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. The business's 50-day moving average is $256.44 and its 200-day moving average is $239.47. Ascendis Pharma A/S has a 1 year low of $186.05 and a 1 year high of $282.15.

Insiders Place Their Bets

In other news, Director Jean Jacques Bienaime acquired 2,000 shares of the business's stock in a transaction on Friday, August 14th. The shares were purchased at an average cost of $246.33 per share, with a total value of $492,660.00. Following the acquisition, the director directly owned 2,900 shares of the company's stock, valued at $714,357. The trade was a 222.22% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 40.00% of the company's stock.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nomura Asset Management Co. Ltd. boosted its position in Ascendis Pharma A/S by 57.5% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 43,701 shares of the biotechnology company's stock worth $9,319,000 after purchasing an additional 15,950 shares during the last quarter. Candriam S.C.A. raised its stake in shares of Ascendis Pharma A/S by 23.2% during the 1st quarter. Candriam S.C.A. now owns 230,278 shares of the biotechnology company's stock worth $52,671,000 after purchasing an additional 43,338 shares during the period. Orbimed Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 5.8% during the 1st quarter. Orbimed Advisors LLC now owns 181,977 shares of the biotechnology company's stock worth $41,624,000 after purchasing an additional 10,000 shares during the period. UBS Group AG boosted its holdings in shares of Ascendis Pharma A/S by 57.9% in the 4th quarter. UBS Group AG now owns 308,190 shares of the biotechnology company's stock worth $65,718,000 after buying an additional 112,986 shares during the last quarter. Finally, Cormorant Asset Management LP purchased a new position in shares of Ascendis Pharma A/S in the 4th quarter worth about $21,324,000.

Ascendis Pharma A/S News Roundup

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Ascendis Pharma entered a binding term sheet with BioMarin Pharmaceutical for a global settlement and license agreement related to YUVIWEL (navepegritide). The agreement is intended to resolve all litigation and disputes between the companies, reducing legal uncertainty and potentially improving the commercial outlook for the product. The market reacted favorably, with shares rising after the announcement. Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL
• Positive Sentiment: Analysts continue to rate ASND positively. HC Wainwright maintained a Buy rating and a $345 price target, while Bank of America retained its Buy rating with a $304 target, both implying upside from the stock’s referenced $263.04 level. The stock also received an average Buy rating from covering analysts. Ascendis Pharma Receives Average Rating of Buy from Analysts
• Neutral Sentiment: Bank of America trimmed its price target modestly from $306 to $304 while keeping a Buy rating, signaling slightly reduced valuation expectations but continued confidence in Ascendis Pharma’s prospects.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for every reported period from the third quarter of 2026 through the fourth quarter of 2027. Its FY2027 estimate fell to $11.25 from $11.88, while quarterly estimates were reduced by $0.07 to $0.19. These revisions indicate that the analyst expects somewhat slower near-term earnings growth, despite maintaining the Buy rating and $345 target.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source